Clinical application of histoculture drug response assay (HDRA) for gastrointestinal cancers with reference to cumulative efficacy rate curve

Toshiharu Furukawa, K. Suzuki, S. Yuasa, M. Izumo, K. Kozakai, T. Yano, N. Harada, T. Kubota

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Histoculture Drug Response Assay (HDRA) with MTT-endpoint was performed using surgical specimens, including 79 gastric and 94 colorectal cancers from 17 hospitals. Surgical specimens were cut into pieces, placed onto collagen-gel-matrix in the medium containing each concentration of mitomycin C (MMC), 5-fluorouracil (5-FU), adriamycin (ADM) and cisplatin (DDP), and incubated for 7 days. At the end of incubation, the viability of tumor cells was evaluated according MTT methods, in which fifty percent or more inhibition rate at each concentration was evaluated as positive. Ninety percent gastric and ninety-three percent colorectal cancer cases were evaluable. Using the cumulative efficacy rate curve, the optimal cutoff concentrations were estimated as 2 μg/ml for MMC, 300 μg/ml for 5-FU, 15 μg/ml for ADM and 20 μg/ml for DDP. Efficacy rates obtained from these cutoff concentrations were 32.7% for MMC, 20.0% for 5-FU, 11.9% for ADM and 8.8% for DDP in gastric cancer, and 15.9% for MMC, 19.7% for 5-FU, 9.6% for ADM and 6.6% for DDP in colorectal cancer. These cutoff concentrations obtained from cumulative efficacy rate curves were essentially identical to those in our previous report. And high sensitivity to 5-FU and low sensitivity of DDP in colorectal cancer were successfully reproduced in the study. HDRA with MTT-endpoint would be useful for further clinical application.

Original languageEnglish
Pages (from-to)116-126
Number of pages11
JournalJournal of Japan Society for Cancer Therapy
Volume31
Issue number2
Publication statusPublished - 1996

Fingerprint

Gastrointestinal Neoplasms
Fluorouracil
Mitomycin
Doxorubicin
Colorectal Neoplasms
Pharmaceutical Preparations
Stomach
Cancer Care Facilities
Cisplatin
Stomach Neoplasms
Cell Survival
Collagen
Gels
Neoplasms

Keywords

  • collagen-gel
  • cumulative efficacy rate curve
  • histoculture drug response assay
  • MTT assay

ASJC Scopus subject areas

  • Cancer Research

Cite this

Clinical application of histoculture drug response assay (HDRA) for gastrointestinal cancers with reference to cumulative efficacy rate curve. / Furukawa, Toshiharu; Suzuki, K.; Yuasa, S.; Izumo, M.; Kozakai, K.; Yano, T.; Harada, N.; Kubota, T.

In: Journal of Japan Society for Cancer Therapy, Vol. 31, No. 2, 1996, p. 116-126.

Research output: Contribution to journalArticle

@article{3cdec064a0d44671be232ddb1340d149,
title = "Clinical application of histoculture drug response assay (HDRA) for gastrointestinal cancers with reference to cumulative efficacy rate curve",
abstract = "Histoculture Drug Response Assay (HDRA) with MTT-endpoint was performed using surgical specimens, including 79 gastric and 94 colorectal cancers from 17 hospitals. Surgical specimens were cut into pieces, placed onto collagen-gel-matrix in the medium containing each concentration of mitomycin C (MMC), 5-fluorouracil (5-FU), adriamycin (ADM) and cisplatin (DDP), and incubated for 7 days. At the end of incubation, the viability of tumor cells was evaluated according MTT methods, in which fifty percent or more inhibition rate at each concentration was evaluated as positive. Ninety percent gastric and ninety-three percent colorectal cancer cases were evaluable. Using the cumulative efficacy rate curve, the optimal cutoff concentrations were estimated as 2 μg/ml for MMC, 300 μg/ml for 5-FU, 15 μg/ml for ADM and 20 μg/ml for DDP. Efficacy rates obtained from these cutoff concentrations were 32.7{\%} for MMC, 20.0{\%} for 5-FU, 11.9{\%} for ADM and 8.8{\%} for DDP in gastric cancer, and 15.9{\%} for MMC, 19.7{\%} for 5-FU, 9.6{\%} for ADM and 6.6{\%} for DDP in colorectal cancer. These cutoff concentrations obtained from cumulative efficacy rate curves were essentially identical to those in our previous report. And high sensitivity to 5-FU and low sensitivity of DDP in colorectal cancer were successfully reproduced in the study. HDRA with MTT-endpoint would be useful for further clinical application.",
keywords = "collagen-gel, cumulative efficacy rate curve, histoculture drug response assay, MTT assay",
author = "Toshiharu Furukawa and K. Suzuki and S. Yuasa and M. Izumo and K. Kozakai and T. Yano and N. Harada and T. Kubota",
year = "1996",
language = "English",
volume = "31",
pages = "116--126",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Clinical application of histoculture drug response assay (HDRA) for gastrointestinal cancers with reference to cumulative efficacy rate curve

AU - Furukawa, Toshiharu

AU - Suzuki, K.

AU - Yuasa, S.

AU - Izumo, M.

AU - Kozakai, K.

AU - Yano, T.

AU - Harada, N.

AU - Kubota, T.

PY - 1996

Y1 - 1996

N2 - Histoculture Drug Response Assay (HDRA) with MTT-endpoint was performed using surgical specimens, including 79 gastric and 94 colorectal cancers from 17 hospitals. Surgical specimens were cut into pieces, placed onto collagen-gel-matrix in the medium containing each concentration of mitomycin C (MMC), 5-fluorouracil (5-FU), adriamycin (ADM) and cisplatin (DDP), and incubated for 7 days. At the end of incubation, the viability of tumor cells was evaluated according MTT methods, in which fifty percent or more inhibition rate at each concentration was evaluated as positive. Ninety percent gastric and ninety-three percent colorectal cancer cases were evaluable. Using the cumulative efficacy rate curve, the optimal cutoff concentrations were estimated as 2 μg/ml for MMC, 300 μg/ml for 5-FU, 15 μg/ml for ADM and 20 μg/ml for DDP. Efficacy rates obtained from these cutoff concentrations were 32.7% for MMC, 20.0% for 5-FU, 11.9% for ADM and 8.8% for DDP in gastric cancer, and 15.9% for MMC, 19.7% for 5-FU, 9.6% for ADM and 6.6% for DDP in colorectal cancer. These cutoff concentrations obtained from cumulative efficacy rate curves were essentially identical to those in our previous report. And high sensitivity to 5-FU and low sensitivity of DDP in colorectal cancer were successfully reproduced in the study. HDRA with MTT-endpoint would be useful for further clinical application.

AB - Histoculture Drug Response Assay (HDRA) with MTT-endpoint was performed using surgical specimens, including 79 gastric and 94 colorectal cancers from 17 hospitals. Surgical specimens were cut into pieces, placed onto collagen-gel-matrix in the medium containing each concentration of mitomycin C (MMC), 5-fluorouracil (5-FU), adriamycin (ADM) and cisplatin (DDP), and incubated for 7 days. At the end of incubation, the viability of tumor cells was evaluated according MTT methods, in which fifty percent or more inhibition rate at each concentration was evaluated as positive. Ninety percent gastric and ninety-three percent colorectal cancer cases were evaluable. Using the cumulative efficacy rate curve, the optimal cutoff concentrations were estimated as 2 μg/ml for MMC, 300 μg/ml for 5-FU, 15 μg/ml for ADM and 20 μg/ml for DDP. Efficacy rates obtained from these cutoff concentrations were 32.7% for MMC, 20.0% for 5-FU, 11.9% for ADM and 8.8% for DDP in gastric cancer, and 15.9% for MMC, 19.7% for 5-FU, 9.6% for ADM and 6.6% for DDP in colorectal cancer. These cutoff concentrations obtained from cumulative efficacy rate curves were essentially identical to those in our previous report. And high sensitivity to 5-FU and low sensitivity of DDP in colorectal cancer were successfully reproduced in the study. HDRA with MTT-endpoint would be useful for further clinical application.

KW - collagen-gel

KW - cumulative efficacy rate curve

KW - histoculture drug response assay

KW - MTT assay

UR - http://www.scopus.com/inward/record.url?scp=0029887688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029887688&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029887688

VL - 31

SP - 116

EP - 126

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 2

ER -